AI assistant
Immunovant, Inc. — Director's Dealing 2019
Dec 20, 2019
31436_dirs_2019-12-20_6110e5cc-2396-49cb-99ac-da021419a9ac.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Immunovant, Inc. (IMVT)
CIK: 0001764013
Period of Report: 2019-12-18
Reporting Person: Hughes Douglas J. (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-12-18 | Stock Option (right to buy) | $8.43 | A | 77181 | Acquired | 2029-11-19 | Common Stock (77181) | Direct |
Footnotes
F1: This stock option vests over a period of three years, with 1/3 of the shares underlying the option vesting on each of the first, second and third anniversaries of the vesting commencement date.
F2: In connection with the share exchange transaction pursuant to which Health Sciences Acquisitions Corporation ("HSAC") acquired 100% of the issued and outstanding shares of Immunovant Sciences Ltd., the option to purchase 157,812 shares of Immunovant Sciences Ltd. at exercise price of $4.12 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer (formerly known as HSAC).